Yes, please short EPRS, ctbradley11. Their biosimilar for Remicade will be a blockbuster over time, a drug with over $8 billion in annual sales. The formulation works. Yes, because the company is posting large losses with the studies for approval in the EU and the US, it will be a long time until EPRS is close to turning a profit. The market will recognize the potential and patience will be rewarded big to shareholders in this stock.
FYI - EPRS has nothing to do with the old ZLCS. EPRS bought the stock symbol to come public, instead of doing an IPO. EPRS didn't buy anything else of ZLCS, none of the employees or assets of that company are involved with EPRS. It's a new company, and if you happen to own EPRS because of that transaction then you are lucky to be with a real company now, with huge potential biosimilar (generic) versions of enormous drugs which will be going off patent in the next few years.
Any history of the stock symbol prior to July 16th 2014, when Epirus essentially just bought the stock symbol from Zalicus, retaining none of the company or it's employees - all that prior stock price history does not apply. Only the price history from July 16,2014 to today is relevent. Epirus is well funded for their studies to eventually apply for NDA for biosimilar Remicade in 2017, for rollout in 2018 in the US and EU.
Remicade, the JNJ drug, had $8.4 billion in sales in 2013. Epirus already has an effective biosimilar for Remicade on the market in India, where Remicade sells in tiny amounts due to the huge cost of the drug. This is a very solid company with great management, lots of people ex-Amgen and Biogen.
This was in an Israeli publication on Feb, 14. An interview with BizPortal which is an Israeli business publication online, translated from hebrew, about the study he conducted in Germany using PSTI's cells. Very good read. Doesn't seem to have been posted in full.